Simon Pedder
CIK 1316736 · Executive Chairman · last filed 2025-09-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CERC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3540 TORINGDON WAY, SUITE 200, #250
CHARLOTTE, NC 28277
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Athenex, Inc. (ATNX) Delisted | See Remarks | 266 | $0.20 | $54 | $40.8K | 9 | 2021-08-05 |
| Avalo Therapeutics, Inc. (CERC) Delisted | Executive Chairman of the Bd | 241,833 | $2.93 | $708.6K | $50.4K | 8 | 2020-04-13 |
| DCTH | Director | — | $14.71 | — | $0 | 1 | 2019-02-05 |
| Avalo Therapeutics, Inc. (CERCW) Delisted | Director | — | — | — | $0 | 4 | 2018-10-01 |
| Oncotelic Therapeutics, Inc. (OXGN) Delisted | Director | — | — | — | $0 | 2 | 2016-06-03 |
| Cellectar Biosciences, Inc. (CLRB.W) Delisted | President and CEO | 13,300 | — | — | $49.9K | 1 | 2014-08-22 |
| Chelsea Therapeutics International, Ltd. (CHTP) Delisted | Chief Executive Officer | 488,180 | — | — | $23.9K | 9 | 2012-01-27 |
Recent Filings · Page 4 of 4
37 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2010-09-07 | Chelsea Therapeutics International, Ltd. (CHTP) Delisted | Buy (P) | +1,250 | $5.1K | EDGAR |
| 2010-01-21 | Chelsea Therapeutics International, Ltd. (CHTP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-12-21 | Chelsea Therapeutics International, Ltd. (CHTP) Delisted | Mixed | +4,600 | $10.1K | EDGAR |
| 2009-01-26 | Chelsea Therapeutics International, Ltd. (CHTP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-09-24 | Chelsea Therapeutics International, Ltd. (CHTP) Delisted | Buy (P) | +3,000 | $8.7K | EDGAR |
| 2008-01-28 | Chelsea Therapeutics International, Ltd. (CHTP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-02-08 | Chelsea Therapeutics International, Ltd. (CHTP) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.